Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Groupama Asset Managment

Groupama Asset Managment grew its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 41.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 110,207 shares of the company’s stock after acquiring an additional 32,162 shares during the period. Groupama Asset Managment’s holdings in Denali Therapeutics were worth $2,231,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. The Manufacturers Life Insurance Company raised its position in shares of Denali Therapeutics by 20.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 206,819 shares of the company’s stock worth $6,025,000 after acquiring an additional 34,538 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Denali Therapeutics by 230.2% during the third quarter. BNP Paribas Financial Markets now owns 27,625 shares of the company’s stock worth $805,000 after purchasing an additional 19,259 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Denali Therapeutics by 12.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,719 shares of the company’s stock worth $866,000 after purchasing an additional 3,316 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Denali Therapeutics during the 3rd quarter worth approximately $792,000. Finally, Holocene Advisors LP boosted its holdings in shares of Denali Therapeutics by 65.0% in the 3rd quarter. Holocene Advisors LP now owns 97,447 shares of the company’s stock valued at $2,839,000 after buying an additional 38,405 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the transaction, the chief executive officer now directly owns 260,721 shares in the company, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,860 shares of company stock valued at $909,039. 7.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DNLI shares. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. B. Riley reissued a “buy” rating and issued a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Morgan Stanley started coverage on Denali Therapeutics in a research report on Friday, March 7th. They set an “overweight” rating and a $33.00 price target on the stock. Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price objective for the company. Finally, Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.20.

Denali Therapeutics Stock Up 11.8 %

NASDAQ DNLI opened at $13.74 on Thursday. The stock has a market capitalization of $2.00 billion, a P/E ratio of -4.98 and a beta of 1.58. Denali Therapeutics Inc. has a 52-week low of $12.05 and a 52-week high of $33.33. The firm has a 50-day moving average price of $18.48 and a 200 day moving average price of $22.91.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.